Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $44.83.

OMCL has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday, May 20th. Wells Fargo & Company reiterated an "overweight" rating and set a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Benchmark reduced their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Finally, Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd.

Omnicell Stock Up 1.6%

OMCL traded up $0.46 during trading on Wednesday, hitting $29.83. 574,267 shares of the company's stock traded hands, compared to its average volume of 567,023. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.75. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of 110.49, a PEG ratio of 7.53 and a beta of 0.78. The company's 50 day simple moving average is $30.61 and its two-hundred day simple moving average is $38.34.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The company had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. During the same period in the previous year, the business earned $0.03 earnings per share. Omnicell's quarterly revenue was up 9.5% compared to the same quarter last year. Analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its position in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new stake in Omnicell during the fourth quarter worth $37,000. Van ECK Associates Corp lifted its holdings in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Omnicell during the 4th quarter valued at about $53,000. Finally, First Horizon Advisors Inc. lifted its stake in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.